FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108410268> ?p ?o ?g. }

• W2108410268 endingPage "6370" @default.
• W2108410268 startingPage "6360" @default.
• W2108410268 abstract "Abstract The traditional drug development process in breast cancer based on large phase III studies has serious limitations and needs a major overhaul. Searching for new approaches, the testing of novel agents in the preoperative (neoadjuvant) setting approach offers a potentially rapid and efficient strategy for drug development utilizing pathologic complete response (path CR), a surrogate marker for survival, as the primary endpoint. In addition, neoadjuvant studies allow the assessment of drug effects on the target (pharmacodynamic response) and the development of predictive biomarkers of response. Molecular profiling of the residual tumor in the surgical specimen may also provide insights into actionable mechanisms of resistance. Recognizing the potential of neoadjuvant trials for drug development, the U.S. Food and Drug Administration (FDA) recently announced consideration of neoadjuvant trials for accelerated drug approval in early breast cancer, particularly for tumors with high risk of recurrence and unfavorable prognosis, and provided accelerated approval to neoadjuvant pertuzumab in September 2013. The FDA has emphasized that while improvement in path CR could be utilized for “accelerated” approval, improvement in survival will still need to be demonstrated for “regular” approval. Key considerations in conduct of such neoadjuvant drug development trials include (i) study design such as utilization of biomarker stratified design to evaluate a biomarker that could enrich response, (ii) definition of path CR, (iii) distribution of factors that influence path CR between the treatment arms, (iv) prespecified plan for follow-up to obtain data on survival, and (v) safety as it involves a patient population with curable disease. In the years to come, we anticipate an increase in the number of neoadjuvant trials testing novel therapies that hopefully will open a new path in bringing efficacious new therapies to patients with breast cancer. Clin Cancer Res; 19(23); 6360–70. ©2013 AACR." @default.
• W2108410268 created "2016-06-24" @default.
• W2108410268 creator A5004300577 @default.
• W2108410268 creator A5034972183 @default.
• W2108410268 date "2013-12-01" @default.
• W2108410268 modified "2023-09-27" @default.
• W2108410268 title "Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer" @default.
• W2108410268 cites W1523531555 @default.
• W2108410268 cites W1892756525 @default.
• W2108410268 cites W1955397179 @default.
• W2108410268 cites W1987326983 @default.
• W2108410268 cites W1993702531 @default.
• W2108410268 cites W2003492008 @default.
• W2108410268 cites W2017098623 @default.
• W2108410268 cites W2017832231 @default.
• W2108410268 cites W2018669222 @default.
• W2108410268 cites W2024484688 @default.
• W2108410268 cites W2050126859 @default.
• W2108410268 cites W2063432148 @default.
• W2108410268 cites W2064044903 @default.
• W2108410268 cites W2071697907 @default.
• W2108410268 cites W2082239705 @default.
• W2108410268 cites W2087179076 @default.
• W2108410268 cites W2095704084 @default.
• W2108410268 cites W2098775844 @default.
• W2108410268 cites W2104505549 @default.
• W2108410268 cites W2105400786 @default.
• W2108410268 cites W2109189228 @default.
• W2108410268 cites W2110477000 @default.
• W2108410268 cites W2111578514 @default.
• W2108410268 cites W2113435829 @default.
• W2108410268 cites W2114428747 @default.
• W2108410268 cites W2118145600 @default.
• W2108410268 cites W2122574381 @default.
• W2108410268 cites W2123591186 @default.
• W2108410268 cites W2131256900 @default.
• W2108410268 cites W2142486051 @default.
• W2108410268 cites W2144099154 @default.
• W2108410268 cites W2146384083 @default.
• W2108410268 cites W2147100784 @default.
• W2108410268 cites W2147299492 @default.
• W2108410268 cites W2149719146 @default.
• W2108410268 cites W2149908785 @default.
• W2108410268 cites W2150757282 @default.
• W2108410268 cites W2153061474 @default.
• W2108410268 cites W2166199281 @default.
• W2108410268 cites W2167188058 @default.
• W2108410268 cites W2171632978 @default.
• W2108410268 cites W2171958606 @default.
• W2108410268 cites W2284087652 @default.
• W2108410268 cites W2316247073 @default.
• W2108410268 cites W4239258335 @default.
• W2108410268 doi "https://doi.org/10.1158/1078-0432.ccr-13-0916" @default.
• W2108410268 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24298066" @default.
• W2108410268 hasPublicationYear "2013" @default.
• W2108410268 type Work @default.
• W2108410268 sameAs 2108410268 @default.
• W2108410268 citedByCount "75" @default.
• W2108410268 countsByYear W21084102682013 @default.
• W2108410268 countsByYear W21084102682014 @default.
• W2108410268 countsByYear W21084102682015 @default.
• W2108410268 countsByYear W21084102682016 @default.
• W2108410268 countsByYear W21084102682017 @default.
• W2108410268 countsByYear W21084102682018 @default.
• W2108410268 countsByYear W21084102682019 @default.
• W2108410268 countsByYear W21084102682020 @default.
• W2108410268 countsByYear W21084102682021 @default.
• W2108410268 countsByYear W21084102682022 @default.
• W2108410268 countsByYear W21084102682023 @default.
• W2108410268 crossrefType "journal-article" @default.
• W2108410268 hasAuthorship W2108410268A5004300577 @default.
• W2108410268 hasAuthorship W2108410268A5034972183 @default.
• W2108410268 hasConcept C121608353 @default.
• W2108410268 hasConcept C126322002 @default.
• W2108410268 hasConcept C141341695 @default.
• W2108410268 hasConcept C143998085 @default.
• W2108410268 hasConcept C177713679 @default.
• W2108410268 hasConcept C185592680 @default.
• W2108410268 hasConcept C203092338 @default.
• W2108410268 hasConcept C2778292576 @default.
• W2108410268 hasConcept C2780035454 @default.
• W2108410268 hasConcept C2781197716 @default.
• W2108410268 hasConcept C2908647359 @default.
• W2108410268 hasConcept C530470458 @default.
• W2108410268 hasConcept C535046627 @default.
• W2108410268 hasConcept C55493867 @default.
• W2108410268 hasConcept C64903051 @default.
• W2108410268 hasConcept C71924100 @default.
• W2108410268 hasConcept C98274493 @default.
• W2108410268 hasConcept C99454951 @default.
• W2108410268 hasConceptScore W2108410268C121608353 @default.
• W2108410268 hasConceptScore W2108410268C126322002 @default.
• W2108410268 hasConceptScore W2108410268C141341695 @default.
• W2108410268 hasConceptScore W2108410268C143998085 @default.
• W2108410268 hasConceptScore W2108410268C177713679 @default.
• W2108410268 hasConceptScore W2108410268C185592680 @default.
• W2108410268 hasConceptScore W2108410268C203092338 @default.
• W2108410268 hasConceptScore W2108410268C2778292576 @default.

• next